Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab, allows access to affordable treatment for patients.

The Delhi High Court has cleared Zydus Lifesciences to manufacture and sell a biosimilar version of Bristol Myers Squibb's cancer drug Nivolumab. The ruling overturns a previous order that had temporarily restrained Zydus from launching the biosimilar. The court's decision allows Zydus to proceed with sales, directing the company to maintain detailed accounts until the patent lapses on May 2.